For most people, a cancer diagnosis—especially one such as chronic lymphocytic leukemia (CLL), a slow-growing type of blood cancer—sets off a flood of emotions. According to a 2022 Emotional Impact ...
For patients with chronic lymphocytic leukemia (CLL), minimal residual disease (MRD) has emerged as a highly sensitive indicator of disease burden during and at the end of treatment, and has ...
Margaret Krackeler, MD, discusses real-world data supporting the switch from ibrutinib to zanubrutinib for chronic lymphocytic leukemia.
Researchers sought to compare the safety and efficacy of pirtobrutinib monotherapy vs bendamustine plus rituximab among treatment-naïve patients with CLL/SLL.
Nicole Lamanna, MD: There are several unmet needs in chronic lymphocytic leukemia that have changed over time. Initially, the biggest unmet need happened to be in the patients with the 17p deletion.
The episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted ...
Venetoclax demonstrated a 91% overall response rate and 44% complete response rate in octogenarians with CLL, comparable to younger cohorts. Common adverse events included neutropenia (37%) and grade ...
About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results